Biotech | April 25, 2022
Shilpa Medicare receives NoC for biosimilar Aflibercept
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Ideal power boosters to strengthen muscles and keep energised for all kinds of physical activities
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Routine tests undertaken by women dropped by 35% in 2020
Price was the key driver for the period
Subscribe To Our Newsletter & Stay Updated
